. 2021 Dec 30;57(4):568–574. doi: 10.1177/00185787211066460

Table 4.

Group Comparison on Continuous Outcomes.

Outcome variable	Drug	N (patients)	Group Comparison			Adjusted/conditional group comparison^*
Outcome variable	Drug	N (patients)	Mean	SD	P ^{^}	Mean	Coefficient	Std. error	95% CI of mean dif.	P
Days of therapy	Ertapenem	55	6.64	2.69	.124	6.61	–0.806	0.564	(–1.91 to 0.30)	.157
Days of therapy	Cefoxitin	30	5.77	1.98	.124	5.81	–0.806	0.564	(–1.91 to 0.30)	.157
Days to WBC normalization	Ertapenem	13	3.85	3.00	.560	3.80	–0.758	1.102	(–2.96 to 1.45)	.499
Days to WBC normalization	Cefoxitin	10	3.20	1.93	.560	3.04	–0.758	1.102	(–2.96 to 1.45)	.499
Days to defervescence	Ertapenem	17	1.47	0.72	.131	1.51	1.003	0.509	(–0.02 to 2.02)	.064
Days to defervescence	Cefoxitin	4	2.25	1.50	.131	2.51	1.003	0.509	(–0.02 to 2.02)	.064

^{^}

Calculated using independent samples t-test.

Adjustment in group differences performed by including the Charlson Comorbidity Index as a covariate in the Ordinary Last Square (OLS) regression model.